Goldman Sachs
BOLD

Goldman Sachs’s Boundless Bio BOLD Stock Holding History

Goldman Sachs’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,299
Closed -$17.6K – 6883
2025
Q3 		$17.6K Sell
14,299
-56,005
-80% -$64.6K ﹤0.01% 6238
2025
Q2 		$71K Buy
70,304
+35,877
+104% +$47.7K ﹤0.01% 5877
2025
Q1 		$52K Sell
34,427
-14,245
-29% -$29.5K ﹤0.01% 5875
2024
Q4 		$141K Buy
48,672
+37,316
+329% +$109K ﹤0.01% 5703
2024
Q3 		$39.4K Buy
+11,356
New +$41.2K ﹤0.01% 5646

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs's BOLD Position: Q4 2025 in Review

Goldman Sachs sold out of Boundless Bio (BOLD) in Q4 2025, closing a stake of 14,299 shares — an estimated $17.6K sold.

Goldman Sachs first reported a position in BOLD in Q3 2024 and held it in 5 quarters. The position peaked at $141K in Q4 2024. 36 funds tracked by Wall St. Rank hold BOLD as of Q4 2025.

  • Goldman Sachs reported no remaining Boundless Bio position as of Q4 2025 after selling out during the quarter.
  • Goldman Sachs sold 14,299 Boundless Bio shares in Q4 2025, an estimated $17.6K.
  • Goldman Sachs first reported a position in Boundless Bio in Q3 2024 and held it in 5 quarters.
  • Goldman Sachs's Boundless Bio position peaked at $141K in Q4 2024.
  • 36 funds tracked by Wall St. Rank held Boundless Bio as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.